Crossject obtient 6,9 millions d'euros de financement public dans le cadre du plan France 2030, pour accélérer le développement de ZENEO® Adrénaline
July 10, 2024 01:30 ET
|
CROSSJECT
Contribution clé à l'accélération du développement de ZENEO® AdrénalineSoutien financier composé majoritairement de subventions, et d’avances remboursablesFrance 2030 a vocation à soutenir les...
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
July 10, 2024 01:30 ET
|
CROSSJECT
Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French...